Opicinumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOpicinumab

Drug Alias NameOpicinumabum奥匹努单抗奥匹奴人单抗Anti-LINGO-1BIIB-033 +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionCell differentiation stimulantsLeucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitors

TargetsLeucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1

Therapy Area/IndicationsNeurodegenerative DiseasesOptic NeuritisMultiple Sclerosis, Relapsing-Remitting +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumCanada +[19]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiogen Inc

Active IndicationsN/A

Inactive IndicationsNeurodegenerative DiseasesOptic NeuritisMultiple Sclerosis, Relapsing-Remitting +[4]

Other Information

ATC CodeN/A